Stem cell breakthrough could restore sight for blind people by repairing retinal vessels

Scientists at Duke University have taken a major step toward restoring sight by growing the precise blood-vessel cells the retina needs to function and using them to repair damaged tissue in mice. The lab-developed cells plugged into injured retinal vasculature, rebuilt vessel networks and reinstated barrier function—offering a potential route to treat conditions that cause vision loss in working-age adults.

The work, led by biomedical engineers at Duke and published in Nature Biomedical Engineering, used induced pluripotent stem cells (iPSCs) to create retinal endothelial cells — the specialized lining of tiny blood vessels in the eye. Early tests show these cells can both model disease in the lab and integrate into living retina to form healthy vasculature, a combination that could speed development of new therapies for disorders such as diabetic retinopathy.

Turning iPSCs into retinal blood-vessel cells: the lab process and why it matters

Researchers started with commercially available human iPSCs and guided them through a staged transformation into endothelial cells, then further refined them into the specific subtype found in the retina. This approach builds on the ability to reprogram adult cells into pluripotent ones — a discovery recognized with the Nobel Prize for Shinya Yamanaka — and applies it to a cell type that’s been difficult to obtain at scale.

Key steps the team used included:

• Culturing iPSCs under conditions that encourage vascular endothelial fate.
• Applying a targeted cocktail of growth factors to push those endothelial cells toward a retinal identity.
• Testing the resulting cells for the molecular markers and behaviors that define retinal endothelial cells.

By producing these cells from iPSCs instead of harvesting them from patients, researchers can reduce variability between samples and create a more consistent, cost-effective supply for both experiments and future therapies.

Building a realistic disease model: testing under diabetic-like stress

In the lab, the engineered retinal endothelial cells assembled into networks that mimicked the architecture of retinal vessels. To test resilience and disease relevance, scientists exposed the tissues to environmental stressors commonly seen in eye disease patients: low oxygen (hypoxia) and high glucose levels.

Those conditions caused the lab-grown barriers to break down in ways similar to diabetic retinopathy, demonstrating that the engineered tissue can reproduce important features of human retinal disease. That capability lets researchers:

• Study how blood-retinal barriers fail during illness.
• Screen drug candidates in a controlled, human-relevant system.
• Refine cell therapies before moving to animal or clinical studies.

Repairing mouse retinas: cells integrate and rebuild functional vessels

When the retinal endothelial cells were injected into mouse models that mimic retinal vascular disease, they incorporated into existing tissue and helped form robust vessels with effective barrier properties. Importantly, injections made prior to overt vision loss preserved retinal integrity, suggesting a potential role for these cells in early or preventative interventions.

Scientists observed that the lab-grown cells did more than survive—they reorganized into vessel networks that supported the retinal tissue’s needs for oxygen and nutrients. According to members of the Duke team, this makes the cells promising candidates for therapies that aim to halt vascular breakdown before severe vision impairment occurs. Early data point to the cells’ potential to serve as both a treatment and a platform for discovering drugs that protect vision.

Why retinal endothelial cells are critical — and why they’re hard to treat

The retina functions as an extension of the brain and is protected by a strict blood-retinal barrier that controls what reaches delicate neural tissue. While this barrier is vital for normal vision, it also blocks many treatments and complicates efforts to repair damaged retinal vessels.

Retinal endothelial cells form the inner lining of those tiny vessels and help maintain barrier integrity. When they deteriorate, fluid and harmful molecules can leak into retinal tissue, triggering inflammation and progressive vision loss. That’s why regenerating healthy retinal endothelial cells could be transformative: restoring barrier function addresses a root cause of several sight-threatening conditions rather than just treating symptoms.

Potential benefits: accessibility, affordability, and improved drug testing

Developing retinal endothelial cells from iPSCs could yield multiple practical advantages:

• Scalable supply: Manufacturing cells from iPSCs avoids the limited availability of donor-derived tissue.
• Lower cost: Standardized production reduces the expense associated with rare primary cell sources.
• Better disease models: Consistent human cell models enable more accurate drug screening and mechanistic studies.
• Personalized approaches: iPSCs derived from patients could be used to test individualized responses to therapies.

Next steps: translating lab success into therapies and partnerships

The Duke team plans to expand studies in the lab and explore commercial collaborations to move the technology toward clinical use. Their work supports both therapeutic development and the creation of in vitro platforms for drug discovery. The researchers also have a patent application pending that covers the stem cell-based therapeutic approach and methods for modeling retinal tissue for testing.

Lead investigator Sharon Gerecht and co-researchers emphasize that more work remains to validate safety and efficacy across a wider range of disease scenarios, but they are optimistic about the value of a renewable source of retinal endothelial cells. Parker Esswein, a doctoral researcher on the project, noted the practical advantages of an easier-to-obtain cell supply for researchers and companies focused on vision science. The combination of disease modeling and reparative ability in living tissue sets a pathway toward new clinical strategies for preventing and treating retinal vascular diseases.

You might also like:

• DMT, the spirit molecule, protects brain from stroke in mice, study finds
• Type 1 diabetes reversed in mice by Stanford without insulin or immune suppression
• Vitamin K may form basis for new treatment for neurodegenerative diseases
• Tuberculosis DNA vaccine nasal delivery shows therapeutic promise in Johns Hopkins study
• Treatment-resistant breast cancer: antibody breakthrough offers new hope

Michael Thompson

Michael Thompson is an experienced journalist covering U.S. and global news. With ten years on the front lines, he breaks down political and economic stories that matter. His precise writing and keen attention to detail help you grasp the real‑world impact of every event.